(2008) Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era. Targeted Oncology 3 , 223-225 /Eric, Van CutsemSabine, Tejpar. (2008) Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era. Targeted Oncology 3 , ...
Current Colorectal Cancer ReportsNele Boeckx, Ken Op de Beeck, Vanessa Deschoolmeester, Guy Van Camp, Patrick Pauwels, Marc Peeters. (2014) Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. Current Colorectal Cancer Reports 10 , 380-394 /...
Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal ...
metastatic colorectal cancerIntroduction Monoclonal antibodies binding the EGFR, such as cetuximab and panitumumab, have been extensively used as targeted therapy for the treatment of mCRC. However, in clinical practice, it has been found that these treatment options have some limitations and fail to ...
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or panitumumab, in combination with chemotherapy are effective treatment options for patients with RAS and BRAF wild-type mCRC...
Currently, KRAS is the only potential biomarker for predicting the efficacy of anti-EGFR monoclonal antibodies (mAb) in colorectal cancer (CRC). However, ... Y Tomoya - Anti-Cancer Agents in Medicinal Chemistry 被引量: 153发表: 2012年 Novel approaches to treatment of advanced colorectal cancer...
Molecular markers for the prediction of anti-EGFR monoclonal antibody treatment efficacy in metastatic colorectal cancer. J Cancer Ther. 2011;2:675-682.Molecular markers for the prediction of anti-EGFR monoclonal antibody treatment efficacy in metastatic colorectal cancer. Han CB,Ma JT,Li F,et al....
The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-typeRASproto-oncogenes. However, a percentage of patients do not respond to this treatment. In addition to mutations in theRAS...
Br J Cancer 97: 1139 – 1145 Grothey A (2010) EGFR antibodies in colorectal cancer: where do they belong? J Clin Oncol 28: 4668 – 4670 Hemmings C, Broomfield A, Bean E, Whitehead M, Yip D (2009) Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but ...
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer The use of KRAS mutations as a selection biomarker for anti-EGFR monoclonal antibody (eg, panitumumab or cetuximab) treatment is the first major step ... Salvatore Siena, Andrea ...